The FDA approved Eli Lilly’s Alzheimer’s disease drug Kisunla, which targets amyloid beta plaques in the brain. The drug showed a significant slowdown in cognitive decline and clearance of amyloid plaques in clinical trials. The approval was delayed due to regulatory setbacks related to trial design and data collection. Kisunla comes with a black box warning for serious side effects, particularly in patients with the ApoE 4 gene. Comparing pricing with other Alzheimer’s drugs like Leqembi, Kisunla allows for shorter treatment durations and less frequent dosing, potentially reducing overall costs for patients. Medicaid and Medicare coverage for Kisunla is available.
Source link
Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi
